Clinical Trials Logo

Clinical Trial Summary

Phase IV, open-labeled, randomized and multicenter clinical trial to demonstrate the superiority of antibiotics with authorized indication for 7 days versus 14 days in the treatment of bloodstream infections produced by P. aeruginosa (BSI-PA).

Clinical Trial Description

The project is designed to determine the optimal duration of antibiotic treatment for Pseudomonas aeruginosa bacteremia, by comparing an adequate antibiotic treatment regimen of 7 days (experimental arm) with another of 14 days (control arm). The evaluation of infection recurrences, mortality, number of free days of antibiotic treatment, adverse events and superinfections are included as secondary objectives. Active antibiotic treatment will be considered any treatment with proven in vitro activity against the strain responsible for the patient's bacteremia, regardless of the administered dose. Clinical rules are included in order to stop antibiotic treatment or continuation and re-evaluation in each arm of treatment. This is a pragmatic study as the number or visits performed for the study are similar to the normal clinical follow-up for this patients. Final contact and final visit for the study will be performed at 90 days after the first positive blood culture. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05210439
Study type Interventional
Source Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Contact Clara M Rosso Fernández, MD-PhD
Phone +34955013414
Status Recruiting
Phase Phase 4
Start date April 28, 2022
Completion date September 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Completed NCT02400268 - Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae Phase 3
Recruiting NCT04070820 - Combination Treatment for Enterococcus Faecalis Bacteriemia Multicenter, Observational Study"
Completed NCT03147807 - BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU N/A
Completed NCT05411315 - Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment N/A
Enrolling by invitation NCT05880069 - Clinical Outcomes in Patients With Infection by Resistant Microorganism
Terminated NCT04250168 - Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Terminated NCT04876430 - Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems Phase 2/Phase 3
Completed NCT03255759 - Actionable Results: Bloodstream Infection Molecular Assay Evaluation N/A
Active, not recruiting NCT03744728 - Genotypic Versus Phenotypic Susceptibility Testing of Positive Blood Cultures N/A
Terminated NCT00680459 - Ethanol Locks for the Treatment of Central Venous Line Infections Phase 3
Recruiting NCT04839653 - Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria N/A
Recruiting NCT03896893 - Neonatal Bacterial Colonization Study N/A
Completed NCT05277350 - A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects Phase 1
Recruiting NCT00843804 - Surveillance for Nosocomial Infections in Pediatric Cancer Patients N/A
Completed NCT00467272 - Catheter Related - Gram Positive Bloodstream Infections Phase 2
Recruiting NCT04658017 - GARNETâ„¢ Filter (GARNET Device) IDE Used in Chronic Hemodialysis Patients With a Bloodstream Infection N/A
Completed NCT04710212 - Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
Not yet recruiting NCT06271031 - Process Mapping and Data Collection to Inform a Computer Simulation Model of Hospitalised Patients With Bloodstream Infection, Sepsis and Systemic Infection
Not yet recruiting NCT03991793 - Granzyme A in Patients With E. Coli Bacteremic Urinary Tract Infections